📣 VC round data is live. Check it out!

Microba Life Sciences Valuation Multiples

Discover revenue and EBITDA valuation multiples for Microba Life Sciences and similar public comparables like Rhythm Biosciences, LSL Pharma Group, Genematrix, Harvard Apparatus and more.

Microba Life Sciences Overview

About Microba Life Sciences

Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome and engages in providing gut microbiome testing services globally to consumers, clinicians, and researchers. It is also involved in developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. The company's operating segments are: Testing Services and Supplements, which derive key revenue, and Research and Development. Geographically, the company derives maximum revenue from Australia and the rest from Europe, New Zealand, the United States, Asia, and other regions.


Founded

2017

HQ

Australia

Employees

52

Financials (LTM)

Revenue: $11M
EBITDA: ($9M)

EV

$24M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Microba Life Sciences Financials

Microba Life Sciences reported last 12-month revenue of $11M and negative EBITDA of ($9M).

In the same LTM period, Microba Life Sciences generated $6M in gross profit, ($9M) in EBITDA losses, and had net loss of ($12M).


Microba Life Sciences P&L

In the most recent fiscal year, Microba Life Sciences reported revenue of $11M and EBITDA of ($8M).

Microba Life Sciences is unprofitable as of last fiscal year, with gross margin of 47%, EBITDA margin of (67%), and net margin of (87%).

See analyst estimates for Microba Life Sciences
LTMLast FY202320242025202620272028
Revenue$11M$11M$6M$10M$11M
Gross Profit$6M$5M$3M$5M$5M
Gross Margin49%47%49%48%48%
EBITDA($9M)($8M)($10M)($10M)($8M)
EBITDA Margin(79%)(67%)(161%)(99%)(71%)
EBIT Margin(101%)(135%)(269%)(185%)(126%)
Net Profit($12M)($10M)($12M)($12M)($11M)
Net Margin(105%)(87%)(186%)(126%)(101%)

Financial data powered by Morningstar, Inc.

Microba Life Sciences Stock Performance

Microba Life Sciences has current market cap of $30M, and enterprise value of $24M.


Microba Life Sciences' stock price is $0.05.

Microba Life Sciences has an EPS (earnings per share) of $-0.02.

See more trading valuation data for Microba Life Sciences
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$24M$30M-9.1%———$-0.02

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Microba Life Sciences Valuation Multiples

Microba Life Sciences trades at 2.1x EV/Revenue multiple, and (2.7x) EV/EBITDA.

See NTM and 2027E valuation multiples for Microba Life Sciences

Microba Life Sciences Financial Valuation Multiples

As of May 23, 2026, Microba Life Sciences has market cap of $30M and EV of $24M.

Microba Life Sciences has a P/E ratio of (2.5x).

LTMLast FY202320242025202620272028
EV/Revenue2.1x2.2x3.9x2.4x2.1x
EV/EBITDA(2.7x)(3.2x)(2.4x)(2.5x)(3.0x)
EV/EBIT(2.1x)(1.6x)(1.4x)(1.3x)(1.7x)
EV/Gross Profit4.4x4.6x7.9x5.1x4.4x
P/E(2.5x)(3.1x)(2.6x)(2.4x)(2.7x)
EV/FCF(1.9x)(2.3x)(1.9x)(1.9x)(2.1x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Microba Life Sciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Microba Life Sciences Margins & Growth Rates

Microba Life Sciences grew revenue by 2% and EBITDA by 15% in the last fiscal year.

In the most recent fiscal year, Microba Life Sciences reported gross margin of 47%, EBITDA margin of (67%), and net margin of (87%).

See estimated margins and future growth rates for Microba Life Sciences

Microba Life Sciences Margins

Last FY202420252026202720282029
Gross Margin47%48%48%54%
EBITDA Margin(67%)(99%)(71%)(54%)
EBIT Margin(135%)(185%)(126%)(68%)
Net Margin(87%)(126%)(101%)(77%)
FCF Margin(95%)(126%)(103%)(75%)

Microba Life Sciences Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth2%59%14%25%
Gross Profit Growth6%55%15%39%
EBITDA Growth15%(2%)(18%)(4%)
EBIT Growth(27%)9%(22%)(32%)
Net Profit Growth26%7%(8%)(5%)
FCF Growth18%(1%)(7%)(9%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Microba Life Sciences Operational KPIs

Microba Life Sciences' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.4M for the same period.

Microba Life Sciences' Rule of 40 is (29%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Microba Life Sciences' Rule of X is 8% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Microba Life Sciences
LTMLast FY202320242025202620272028
Rule of 40(35%)(29%)———
Bessemer Rule of X31%8%———
Revenue per Employee—$0.2M———
Opex per Employee—$0.4M———
S&M Expenses to Revenue—4%8%5%4%
G&A Expenses to Revenue—108%114%105%107%
R&D Expenses to Revenue—13%115%46%13%
Opex to Revenue—205%318%233%202%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Microba Life Sciences Competitors

Microba Life Sciences competitors include Rhythm Biosciences, LSL Pharma Group, Genematrix, Harvard Apparatus, Genoway, Nexsen, Cryosite, Nanologica, AnteoTech and Abingdon Health.

Most Microba Life Sciences public comparables operate across Laboratory Services, Life Sciences Tools, Diagnostics & Genomics, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Rhythm Biosciences1631.7x—(11.5x)—
LSL Pharma Group2.9x—36.2x—
Genematrix2.7x—(24.7x)—
Harvard Apparatus————
Genoway1.8x1.7x7.4x9.6x
Nexsen————
Cryosite4.1x—17.1x—
Nanologica11.2x—(6.8x)—

This data is available for Pro users. Sign up to see all Microba Life Sciences competitors and their valuation data.

Start Free Trial

Microba Life Sciences Funding History

Before going public, Microba Life Sciences raised $10M in total equity funding, across 2 rounds.


Microba Life Sciences Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Jun-19Strategic investmentMicrogen Plc$3M——
Apr-18Series AAlium Capital$7M—Microba Life Sciences is a microbiome analysis company founded in 2017 by Philip Hugenholtz and Gene Tyson, based in Brisbane, Australia. The company specializes in gut microbiome testing services, offering the Microba Insight Sampling Kit to consumers, healthcare practitioners, and researchers, alongside a Metagenomic Analysis Platform (MAP) for research studies. The company received a Series A investment from Alium Capital in 2018. By 2022, following its ASX IPO which raised $30 million, Microba reported revenue of $4.68 million and had $30.5 million in cash. The company has partnered with synthetic biology leader Ginkgo Bioworks (which made a $3.5 million strategic investment) and International Flavours & Fragrances to develop novel allergy treatments, while advancing its therapeutic development program, including the MAP 315 candidate for ulcerative colitis treatment.

Microba Life Sciences M&A Activity

Microba Life Sciences has acquired 1 company to date.

Last acquisition by Microba Life Sciences was on October 19th 2023. Microba Life Sciences acquired Invivo Healthcare for $14M (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by Microba Life Sciences

Invivo Healthcare
Description
Invivo Healthcare is a United Kingdom-based supplier of nutritional therapeutics and laboratory diagnostics. Headquartered in Sevenoaks, Kent, it distributes practitioner-only formulas for gut health, hormones, and detoxification alongside testing kits for allergies, hormones, and microbiome analysis. Products reach clinics, hospitals, and wellness centers across Europe.
HQ CountryUnited Kingdom
HQ City
Stroud
Deal Date19 Oct 2023
Valuation$14M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Microba Life Sciences acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Microba Life Sciences

When was Microba Life Sciences founded?Microba Life Sciences was founded in 2017.
Where is Microba Life Sciences headquartered?Microba Life Sciences is headquartered in Australia.
How many employees does Microba Life Sciences have?As of today, Microba Life Sciences has over 52 employees.
Is Microba Life Sciences publicly listed?Yes, Microba Life Sciences is a public company listed on Australian Securities Exchange.
What is the stock symbol of Microba Life Sciences?Microba Life Sciences trades under MAP ticker.
When did Microba Life Sciences go public?Microba Life Sciences went public in 2022.
Who are competitors of Microba Life Sciences?Microba Life Sciences main competitors include Rhythm Biosciences, LSL Pharma Group, Genematrix, Harvard Apparatus, Genoway, Nexsen, Cryosite, Nanologica, AnteoTech, Abingdon Health.
What is the current market cap of Microba Life Sciences?Microba Life Sciences' current market cap is $30M.
What is the current revenue of Microba Life Sciences?Microba Life Sciences' last 12 months revenue is $11M.
What is the current revenue growth of Microba Life Sciences?Microba Life Sciences revenue growth (NTM/LTM) is 44%.
What is the current EV/Revenue multiple of Microba Life Sciences?Current revenue multiple of Microba Life Sciences is 2.1x.
Is Microba Life Sciences profitable?No, Microba Life Sciences is not profitable.
What is the current EBITDA of Microba Life Sciences?Microba Life Sciences has negative EBITDA and is not profitable.
What is Microba Life Sciences' EBITDA margin?Microba Life Sciences' last 12 months EBITDA margin is (79%).
What is the current EV/EBITDA multiple of Microba Life Sciences?Current EBITDA multiple of Microba Life Sciences is (2.7x).
What is the current FCF of Microba Life Sciences?Microba Life Sciences' last 12 months FCF is ($12M).
What is Microba Life Sciences' FCF margin?Microba Life Sciences' last 12 months FCF margin is (110%).
What is the current EV/FCF multiple of Microba Life Sciences?Current FCF multiple of Microba Life Sciences is (1.9x).
How many companies Microba Life Sciences has acquired to date?As of May 2026, Microba Life Sciences has acquired 1 company.
What was the largest acquisition by Microba Life Sciences?$14M acquisition of Invivo Healthcare on 19th October 2023 was the largest M&A Microba Life Sciences has done to date.
What companies Microba Life Sciences acquired?Microba Life Sciences acquired Invivo Healthcare.
In how many companies Microba Life Sciences has invested to date?Microba Life Sciences hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Microba Life Sciences

Lists including Microba Life Sciences

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial